{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van As N"],"funding":["Cancer Research UK","Accuray","National Institute for Health Research (NIHR)"],"pagination":["1413-1425"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616714"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["391(15)"],"pubmed_abstract":["Background
Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear.Methods
We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA) level of no more than 20 ng per milliliter were randomly assigned (in a 1:1 ratio) to receive SBRT (36.25 Gy in 5 fractions over a period of 1 or 2 weeks) or control radiotherapy (78 Gy in 39 fractions over a period of 7.5 weeks or 62 Gy in 20 fractions over a period of 4 weeks). Androgen-deprivation therapy was not permitted. The primary end point w"],"journal":["The New England journal of medicine"],"pubmed_title":["Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer."],"pmcid":["PMC7616714"],"funding_grant_id":["NIHR203314","15955"],"pubmed_authors":["Kancherla K","van As N","Loblaw A","Tolan S","Armstrong J","Burnett S","Staffurth J","Wells P","Griffin C","Manning G","Tree A","Williamson E","Pugh J","Dayes I","Hall E","Patel J","Jain S","Frew J","Ostler P","Chu W","Chan A","Naismith O","van der Voet H","Camilleri P","Martin A","Ford D","Price D","Brown S"],"additional_accession":[]},"is_claimable":false,"name":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.","description":"Background
Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear.Methods
We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA) level of no more than 20 ng per milliliter were randomly assigned (in a 1:1 ratio) to receive SBRT (36.25 Gy in 5 fractions over a period of 1 or 2 weeks) or control radiotherapy (78 Gy in 39 fractions over a period of 7.5 weeks or 62 Gy in 20 fractions over a period of 4 weeks). Androgen-deprivation therapy was not permitted. The primary end point w","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T03:57:57.174Z","creation":"2025-04-04T09:58:58.643Z"},"accession":"S-EPMC7616714","cross_references":{"pubmed":["39413377"],"doi":["10.1056/NEJMoa2403365"]}}